Walgreens gets award up to $25M through RRPV assessing CoP using Covid data

Walgreens announced it received a project award valued up to $25 M through the Rapid Response Partnership Vehicle or RRPV to conduct a Phase IV observational clinical study focused on assessing Correlates of Protection CoP , known as responses to a vaccine that predict how well a vaccinated person will be protected from future infections, using COVID-19 vaccine data. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority BARDA , part of the Administration for Strategic Preparedness and Response ASPR in the U.S. Department of Health and Human Services HHS . This partnership underscores a shared commitment to advancing public health through innovative research and leveraging Walgreens’ extensive community pharmacies to increase access and representation in clinical trials. As a leading community pharmacy and front door to the U.S. healthcare system, Walgreens played a pivotal role in the distribution of COVID-19 vaccines and testing throughout the pandemic. Walgreens has administered over 90 million COVID-19 vaccinations to date, showcasing its capacity to handle large-scale health initiatives. Building on this experience, through this collaboration, the BARDA-funded study will utilize select Walgreens community pharmacies as clinical trial sites to assess the effectiveness of FDA-authorized COVID-19 vaccines. This initiative aims to enhance access to clinical research across diverse patient populations, particularly in communities historically underrepresented in clinical trials.